Impaired subcutaneous absorption of insulin in 'brittle' diabetics. 1982

P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti

Twenty-four hour plasma free insulin and blood glucose and intermediary metabolite profiles have been measured in 6 C-peptide deficient 'brittle' diabetic patients, during continuous sc and im insulin infusion. During sc infusion free insulin profiles were erratic and unpredictable. Mean 24 h blood glucose levels were raised at 12.6 +/- 2.1 (SE) mmol/l, and 3-hydroxybutyrate at 0.24 +/- 0.08 mmol/l. Blood lactate (1.88 +/- 0.18 mmol/l) and glycerol (0.084 +/- 0.007) were also elevated. Insulin (im) restored free insulin profiles to the normal pattern as found in 'stable' diabetics on sc infusion, with characteristic post-meal peaks (49 +/- 7, 103 +/- 35, and 95 +/- 34 mU/l) and stable night-time levels. Mean 24 h blood glucose was 6.7 +/- 1.1 mmol/l (P less than 0-.05 compared to sc infusion) and 3-hydroxybutyrate 0.07 +/- 0.02 mmol/l (P less than 0.05). Blood lactate (1.67 +/- 0.08 mmol/l) and glycerol (0.10 +/- 0.02 mmol/l) levels remained abnormal. The ratio of plasma free insulin to insulin dose administered was significantly higher during im infusion. In the 6 'stable' diabetics on sc insulin infusion good blood glucose control (7.1 +/- 0.9 mmol/l) was accompanied by clear post-prandial insulin peaks, and stable nocturnal levels. The results strongly suggest that in one category of 'brittle' diabetics there is defective and erratic sc insulin absorption.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007773 Lactates Salts or esters of LACTIC ACID containing the general formula CH3CHOHCOOR.
D008297 Male Males
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005990 Glycerol A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, or sweetening agent. 1,2,3-Propanetriol,Glycerin,1,2,3-Trihydroxypropane,Glycerine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
May 1983, Diabetes,
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
January 1981, British medical journal (Clinical research ed.),
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
June 1983, Ugeskrift for laeger,
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
July 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
October 1982, Ugeskrift for laeger,
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
March 1963, La Semana medica,
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
April 1982, Clinical pharmacology and therapeutics,
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
December 1979, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
May 1980, Journees annuelles de diabetologie de l'Hotel-Dieu,
P D Home, and M Massi-Benedetti, and G V Gill, and B Capaldo, and G A Shepherd, and K G Alberti
December 1976, Diabetologia,
Copied contents to your clipboard!